Navigation Links
New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)
Date:5/18/2008

Additional Digestive Disease Week data highlight effects of AMITIZA in

patients with IBS-C

SAN DIEGO, May 18 /PRNewswire/ -- New study results indicated that treatment with AMITIZA(R) (lubiprostone) 8 mcg lead to significant relief of overall symptoms of Irritable Bowel Syndrome with Constipation (IBS-C). These results were presented at Digestive Disease Week (DDW) 2008, the largest annual international meeting of digestive disease specialists.

"IBS-C is a multi-symptom disorder and is one of the most common conditions seen by gastroenterologists," said William D. Chey, M.D., primary investigator of the study, University of Michigan Health System. "These data are important because they show that in studies, AMITIZA has demonstrated the ability to improve the overall symptoms reported by patients with IBS-C."

AMITIZA 8 mcg was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2008 for the treatment of IBS-C in women 18 years of age and older, and has been approved since 2006 at a 24 mcg dose for the treatment of Chronic Idiopathic Constipation in adults. These data were among others presented at DDW 2008 that evaluated the effect of AMITIZA for IBS-C.

"AMITIZA is the first ClC-2 channel activator and the only widely available FDA-approved agent for the treatment of IBS-C in adult women in the United States. AMITIZA could provide overall symptom relief for the millions of appropriate patients in the U.S. who suffer from this condition," said Ryuji Ueno, M.D., Ph.D., Ph.D., founder, chairman and chief executive officer, Sucampo Pharmaceuticals (Nasdaq: SCMP). "We are pleased with the body of data on AMITIZA presented at DDW this year. Additional data presented at thi
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.; SucampoPharmaceuticals,
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
2. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
3. BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
4. GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
5. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
6. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
7. VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
8. Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047
9. Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial
10. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
11. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  CytomX, a biopharmaceutical company developing ... announced the promotion of several members of its ... who previously served as vice president of business ... senior vice president of corporate development and strategy. ... as the vice president of business development at ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... 3, 2015  Encision Inc. (PK:ECIA), a medical device ... electrosurgical burns in minimally invasive surgery, today announced financial ... June 30, 2015. The Company posted quarterly ... loss of $213 thousand, or $(0.02) per share. These ... a net loss of $202 thousand, or $(0.02) per ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... NEW YORK, Feb. 2, 2011 Reportlinker.com announces that ... catalogue: US Prebiotics Industry ... report analyzes the US And European markets for Prebiotics ... is further analyzed by the following product segments: Mannan-Oligosaccharide ...
... Feb. 2, 2011 H. D. Smith recently announced ... strategic planning and business development, Robert Appleby to corporate ... vice president marketing.  These appointments are the latest organizational ... address evolving customer needs. Joseph ...
Cached Medicine Technology:US Prebiotics Industry 2US Prebiotics Industry 3US Prebiotics Industry 4US Prebiotics Industry 5US Prebiotics Industry 6US Prebiotics Industry 7H. D. Smith Aligns Leadership Positions to Fill Three Senior Roles 2
(Date:8/4/2015)... ... 04, 2015 , ... In the most recent talcum powder ... report that a new location for pretrial proceedings is under consideration, according to ... warning information at their website, the Talcum Powder Cancer Lawsuit Center. , The ...
(Date:8/4/2015)... ... August 04, 2015 , ... IN AMERICA ... which spotlights treating depression. Depression affects millions of Americans every single year. To ... inform and enlighten viewers with the latest segment produced with the assistance of ...
(Date:8/3/2015)... , ... August 04, 2015 , ... ... Armethia Holt as a 2015-2016 inductee into the NAPW VIP Woman of ... healthcare. With more than 700,000 members and over 200 operating Local Chapters, NAPW ...
(Date:8/3/2015)... ... ... offers the most affordable web design and SEO services for start up companies. Every ... dollar. Every company that is starting out needs to be online in this technology ... a start up need to be online, they need to physically be present and visible ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Since 1978, the ... declined, according to a new publication released today by the AAMC (Association of American ... college graduates over the past three decades, the number of black male applicants to ...
Breaking Medicine News(10 mins):Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 2Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 3Health News:Talcum Powder Lawsuits: Plaintiffs Suggest Middlesex County Transfer 4Health News:National Association of Professional Women Inducts Armethia Holt, CEO at AA&G Group Homes, LLC, Into its VIP Woman of the Year Circle 2Health News:Web SEO Master, a division of SH Web Design & SH Web Commerce, Inc. begins offering Web Design and SEO Services for Start Up Companies located in Indianapolis, Indiana 2Health News:Web SEO Master, a division of SH Web Design & SH Web Commerce, Inc. begins offering Web Design and SEO Services for Start Up Companies located in Indianapolis, Indiana 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4
... In a follow-up study, researchers at Moffitt Cancer Center and ... cancer might experience prolonged fatigue years after their therapy. The ... of CANCER , is a follow-up to a study ... researchers published in CANCER in 2007. "Fatigue ...
... , MONDAY, Dec. 5 (HealthDay News) --,Hospitalized patients ... most common cause of infectious diarrhea in hospitals -- will ... new study indicates. Experts say prevention is key to ... C. difficile . For the study, published Dec. 5 ...
... News) -- Teenagers with autism who also have epilepsy ... The combination means that certain behaviors common among ... front of their faces -- could increase their risk ... to 14 percent of children with epilepsy, the rate ...
... By Alan Mozes HealthDay Reporter , SUNDAY, Dec. ... to face an increased risk for seizures while watching 3-D ... did reveal that about one in five of these children ... including nausea, headaches and dizziness. "Normal people have a ...
... University of New Hampshire Crimes against Children Research Center suggest ... found the percentage of youth who send nude pictures of ... The other found that when teen sexting images do come ... like sex offenders. The studies were carried out by ...
... Barcelona, 1st December, 2011.- A study by researchers Ral ... in Biomedicine (IRB Barcelona) and Pilar Navarro at the ... a new reprogramming mechanism for the expression of genes ... cell. In the study, published in this week,s edition ...
Cached Medicine News:Health News:Follow-up study finds prolonged fatigue for those who had chemotherapy for breast cancer 2Health News:Common Hospital Infection Lengthens Patient Stays 2Health News:3-D TV Doesn't Raise Seizure Risk for Kids With Epilepsy: Study 2Health News:3-D TV Doesn't Raise Seizure Risk for Kids With Epilepsy: Study 3Health News:Concerns about teen sexting overblown, according to new UNH research 2Health News:Discovery of a new reprogramming mechanism for tumor cells 2
Designed to give maximum drying area while taking up minimal bench space....
Used to remove wrinkles from sections and for reorientating embedded tissue....
Compact instrument that quickly dries racks of slides using warm air....
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Medicine Products: